Clinical Trials - New Therapies & Treatments
Clinical Research
Close integration of the Breast Care Center with the basic and translational science program at Baylor is a unique feature of the program. Results learned in the laboratory can be rapidly translated to improvements in patient care. Clinical research in the Smith Breast Center ranges from studies of hereditary breast cancer, prevention, and new imaging techniques to improved surgical and medical treatments.
Clinical Research Areas
Patients seen in the Breast Care Center have the opportunity to participate in a wide array of state-of-the-art nationally and locally initiated, clinical trials focused on prevention and treatment. General research areas are as follows:
- Adjuvant therapy trials carried out by the National Surgical Adjuvant Breast and Bowel Project (NSABP).
- Clinical trials of new selective estrogen receptor modulators.
- Studies of new biologically based therapies, such as inhibitors of the EGF receptor family (IRESSA).
- Trials of new chemotherapeutic agents.
- Prognostic and predictive molecular profiling.
- Trials of promising agents for breast cancer prevention.
- Trials evaluating the role of Herceptin in early breast cancer.
Clinical Trials
- Prevention
- Green Tea Study
- H-19895 Neoadjuvant Trial of Lapatinib for the Treatment of Women with DCIS Breast Cancer
- Early Breast Cancer
- Suppression of Ovarian Function Trial (SOFT)
- B-37 Resected Loco-Regional Relapse Study
- Node-Positive
- B-44-I BETH Study
Trial Assigning Individualized Options for Treatment (Rx) (TAILORx) - Node-Negative
- H-20168 B-42 Letrozole Efficacy Study
- Advanced Breast Cancer
- Biologic Correlative Study: trial of Neoadjuvant Taxotere and Adriamycin/Cytoxan (AC)
- CP-751,871 + Exemestane vs. Exemestane for Postmenopausal Hormone Receptor Positive Cancer
- H-18251 Paclitaxel + Trastuzumab + Lapatinib vs Paclitaxel + Trastuzumab in Women with ERBB2 (HER2) Overexpressing Metastatic Breast Cancer
- Neoadjuvant Taxotere and Adriamycin/Cytoxan (AC): A Validation
- H-20464 Lapatinib and Trastuzumab in Locally Advanced HER2 Overexpressing Breast Cancer
- Supportive Care
- Esomeprazole for Nausea and Vomiting Study